MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-28-2024
Inhibrx Total Liabilities 2011-2026 | INBX
Annual Total Liabilities Inhibrx
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 264 M | 233 M | 98.1 M | 68.3 M | 120 M | 67.6 M | 39.7 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 264 M | 39.7 M | 127 M |
Quarterly Total Liabilities Inhibrx
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 243 M | 238 M | 239 M | 233 M | 200 M | 198 M | 134 M | 98.1 M | 101 M | 97.6 M | 63.9 M | 68.3 M | 68.3 M | 68.3 M | 68.3 M | 60.6 M | 60.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 243 M | 60.6 M | 132 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M |  USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Nanobiotix S.A.
NBTX
|
152 M | $ 30.34 | -0.82 % | $ 286 B |  France |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
344 M | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 95.5 | 3.83 % | $ 27.2 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 24.21 | -1.47 % | $ 3.08 B | USA |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
53 M | $ 3.13 | -1.26 % | $ 315 M | USA |
 |
Codiak BioSciences
CDAK
|
118 M | - | -55.98 % | $ 2.15 M | USA |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Avid Bioservices
CDMO
|
276 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
51.5 M | - | - | $ 1.41 B | USA |
 |
InflaRx N.V.
IFRX
|
13.7 M | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
Immutep Limited
IMMP
|
13.3 M | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Concert Pharmaceuticals
CNCE
|
53.1 M | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
19.6 M | $ 3.83 | -2.3 % | $ 258 B | Britain |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Celsion Corporation
CLSN
|
5.23 M | - | -6.63 % | $ 13.9 M | USA |